Multi-intracellular Pathogen Epitope-based Vaccine
Multi-intracellular Pathogen Epitope-based Vaccine
批准号:
8378738
负责人:
Anne Searls DeGroot
金额:
$31.0万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2014-06-30
关键词:
AdjuvantAerosolsAnimalsAntibodiesAttenuatedAttenuated VaccinesBacteriaBindingBioinformaticsBiological AssayBiological WarfareBurkholderiaBurkholderia malleiBurkholderia pseudomalleiCD8-Positive T-LymphocytesCancer Center Support GrantCategoriesCessation of lifeCollaborationsCombined VaccinesDNADR1 geneDatabasesDevelopmentDoseDrug FormulationsEnzyme-Linked Immunosorbent AssayEpitopesFlow CytometryFrancisella tularensisFundingGene ExpressionGlandersHumanImmunologyIn VitroInfectionLeadLicensureLifeMHC Class II GenesMeasuresMelioidosisModelingNational Institute of Allergy and Infectious DiseaseOutcomePeptidesPeripheral Blood Mononuclear CellPhase I Clinical TrialsPhenotypePopulationProductionProteinsRelative (related person)ResearchResearch PersonnelRouteSepsisSepticemiaSubunit VaccinesSurvivorsTNFRSF10A geneTestingTimeTransgenic MiceTularemiaUniversitiesVaccine DesignVaccinesWarWorld War IIbasebiodefensecell mediated immune responsecytokinedesigngenome databasegenome sequencingimmunogenicimmunogenicityimprovedin vivomRNA Differential Displaysmannovelpathogenprogramsprophylacticprototyperespiratorysuccesstoolvaccine developmentvaccine evaluationvector
中文摘要
在本提案的背景下,我们将使用土拉杆菌(FT)的预先定义的表位,和
英文摘要
In the context of this proposal, we will use pre-existing defined epitopes for Fransicella tularensis (FT), and
using the core TRIAD vaccine design toolkit, define new epitopes for Burkholderia pseudomallei (BPM) and
Burkholderia mallei (BM), the agents of meloidosis and glanders, respectively, for use in an epitope-based multipathogen
prophylactic vaccine. FT has been listed as a Category A biological warfare agent as a result of World
War II and Cold War-era biowarfare research. BPM, the etiological agent of melioidosis, is responsible for an
estimated 20% of septicemias and approximately 40% of deaths due to bacterial sepsis in tropical regions of the
world. BM, a related bacterium, also causes fatal infections (classified as glanders) in man and animals. Like FT,
BM is highly infectious as an aerosol. All three pathogens (FT and BPM/BM) are intracellular bacteria and thus
amenable to attack by cell-mediated immune response. The EpiMatrix epitope-based vaccine design platform has
already yielded a prototype F. tularensis Type A (subsp. tularensis: SCHU S4) vaccine that confers 60%
protection against heterologous lethal respiratory challenge with the live vaccine strain (LVS), an attenuated
subsp. holarctica derivative. To our knowledge no subunit vaccine for tularemia has achieved a comparable level
of protection in this well-developed lethal respiratory challenge model. This milestone was reached over the
course of a 24 month funding period. The same vaccine design tools, made available in the context of this U19
program project, will facilitate the development a novel combined vaccine against the three pathogens. We will
test the combined vaccine components, and optimize dose, delivery vehicle, and adjuvants, in a live challenge
model. In addition to evaluating our epitope-driven vaccine, we will explore whether combining our
FT/BPM/BM multi-pathogen vaccine with the anti-LPS vaccine developed by Dr. Steven Opal and colleagues will
lead to improved protection against live challenge. The challenge studies will be carried out at NERCE in
collaboration with Brown University (Steve Gregory, Steve Opal) investigators. This milestone-driven program
will lead to proof-of-principle (evidence for protection against live challenge) and development of a licensable
multi-pathogen biodefense vaccine within a five year time frame.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ISPRI-HCP: CHO protein impurity immunogenicity risk prediction for improving biosimilar product development and assessing product interchangeability
-
批准号:10620080
-
项目类别:
-
资助金额:$200.0万
-
财政年份:2022
-
负责人:Anne Searls DeGroot
-
依托单位:
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
-
批准号:10216952
-
项目类别:
-
资助金额:$112.35万
-
财政年份:2017
-
负责人:Anne Searls DeGroot
-
依托单位:
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
-
批准号:9362529
-
项目类别:
-
资助金额:$122.12万
-
财政年份:2017
-
负责人:Anne Searls DeGroot
-
依托单位:
Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine
-
批准号:9978692
-
项目类别:
-
资助金额:$113.6万
-
财政年份:2017
-
负责人:Anne Searls DeGroot
-
依托单位:
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease
-
批准号:9410057
-
项目类别:
-
资助金额:$17.7万
-
财政年份:2017
-
负责人:Anne Searls DeGroot
-
依托单位:
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza
-
批准号:9304958
-
项目类别:
-
资助金额:$29.05万
-
财政年份:2016
-
负责人:Anne Searls DeGroot
-
依托单位:
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease
-
批准号:8394488
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Anne Searls DeGroot
-
依托单位:
TRIAD Pilot Projects Core
-
批准号:8378749
-
项目类别:
-
资助金额:$29.88万
-
财政年份:2012
-
负责人:Anne Searls DeGroot
-
依托单位:
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
-
批准号:8508305
-
项目类别:
-
资助金额:$37.64万
-
财政年份:2012
-
负责人:Anne Searls DeGroot
-
依托单位:
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
-
批准号:8313747
-
项目类别:
-
资助金额:$38.14万
-
财政年份:2012
-
负责人:Anne Searls DeGroot
-
依托单位:
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease
-
批准号:8538877
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2012
-
负责人:Anne Searls DeGroot
-
依托单位:
TRIAD Administrative Core
-
批准号:8378747
-
项目类别:
-
资助金额:$30.14万
-
财政年份:2012
-
负责人:Anne Searls DeGroot
-
依托单位:
Vaccine Renaissance Conference at the Institute for Immunology and Informatics
-
批准号:8234928
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2011
-
负责人:Anne Searls DeGroot
-
依托单位:
Vaccine Renaissance Conference at the Institute for Immunology and Informatics
-
批准号:8130107
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2011
-
负责人:Anne Searls DeGroot
-
依托单位:
Vaccine Renaissance Conference at the Institute for Immunology and Informatics
-
批准号:8785889
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2011
-
负责人:Anne Searls DeGroot
-
依托单位:
Vaccine Renaissance Conference at the Institute for Immunology and Informatics
-
批准号:8425079
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2011
-
负责人:Anne Searls DeGroot
-
依托单位:
Novel H1N1 influenza protection via cross-reactive immunity
-
批准号:8049298
-
项目类别:
-
资助金额:$22.15万
-
财政年份:2011
-
负责人:Anne Searls DeGroot
-
依托单位:
Novel H1N1 influenza protection via cross-reactive immunity
-
批准号:8261311
-
项目类别:
-
资助金额:$25.08万
-
财政年份:2011
-
负责人:Anne Searls DeGroot
-
依托单位:
Vaccine Renaissance Conference at the Institute for Immunology and Informatics
-
批准号:8871668
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2011
-
负责人:Anne Searls DeGroot
-
依托单位:
Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)
-
批准号:8114221
-
项目类别:
-
资助金额:$251.09万
-
财政年份:2009
-
负责人:Anne Searls DeGroot
-
依托单位:
海外基金